Recommandations De L'Association Des Urologues Du Canada Sur Le Dépistage Et Le Diagnostic Précoce Du Cancer De La Prostate

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2018 Jan 31

PMID 29381452

Citations 20

Authors

Ricardo A Rendon

Ross J Mason

Karim Marzouk

Antonio Finelli

Fred Saad

Alan So

Phillipe Violette

Rodney H Breau

Affiliations

Soon will be listed here.

Citing Articles

Harmonization of clinical practice guidelines for primary prevention and screening: actionable recommendations and resources for primary care.

Fernandes C, Campbell-Scherer D, Lofters A, Grunfeld E, Aubrey-Bassler K, Cheung H BMC Prim Care. 2024; 25(1):153.

PMID: 38711031 PMC: 11071261. DOI: 10.1186/s12875-024-02388-3.

Patient Communication Preferences for Prostate Cancer Screening Discussions: A Scoping Review.

Fong J, Venables M, DSouza D, Maskerine C Ann Fam Med. 2023; 21(5):448-455.

PMID: 37748915 PMC: 10519764. DOI: 10.1370/afm.3011.

Economic evaluation of prostate cancer risk assessment methods: A cost-effectiveness analysis using population data.

Mohammadi T, Guh D, Tam A, Pataky R, Black P, So A Cancer Med. 2023; 12(19):20106-20118.

PMID: 37740609 PMC: 10587968. DOI: 10.1002/cam4.6587.

Development and External Validation of Partial Proportional Odds Risk Prediction Models for Cancer Stage at Diagnosis among Males and Females in Canada.

Biziaev T, Aktary M, Wang Q, Chekouo T, Bhatti P, Shack L Cancers (Basel). 2023; 15(14).

PMID: 37509208 PMC: 10377619. DOI: 10.3390/cancers15143545.

High infiltration of CD209 dendritic cells and CD163 macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes.

Molina O, LaRue H, Simonyan D, Hovington H, Tetu B, Fradet V Front Immunol. 2023; 14:1205266.

PMID: 37435060 PMC: 10331466. DOI: 10.3389/fimmu.2023.1205266.

References

de la Calle C, Patil D, Wei J, Scherr D, Sokoll L, Chan D . Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. J Urol. 2015; 194(1):65-72. PMC: 4696043. DOI: 10.1016/j.juro.2015.01.091. View

Lujan M, Paez A, Pascual C, Angulo J, Miravalles E, Berenguer A . Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2006; 50(6):1234-40. DOI: 10.1016/j.eururo.2006.04.015. View

Vickers A, Cronin A, Aus G, Pihl C, Becker C, Pettersson K . A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med. 2008; 6:19. PMC: 2474851. DOI: 10.1186/1741-7015-6-19. View

Aubin S, Reid J, Sarno M, Blase A, Aussie J, Rittenhouse H . PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010; 184(5):1947-52. DOI: 10.1016/j.juro.2010.06.098. View

Vickers A, Vertosick E, Sjoberg D, Roobol M, Hamdy F, Neal D . Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. J Urol. 2016; 197(3 Pt 1):607-613. PMC: 5315584. DOI: 10.1016/j.juro.2016.09.086. View

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J . Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2007; 19(2):175-81. PMC: 3064270. DOI: 10.1007/s10552-007-9083-8. View

Bradley L, Palomaki G, Gutman S, Samson D, Aronson N . Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol. 2013; 190(2):389-98. DOI: 10.1016/j.juro.2013.02.005. View

Resnick M, Smith Jr J, Scardino P, Egger M, Hernandez A, Rose S . Transrectal prostate ultrasonography: variability of interpretation. J Urol. 1997; 158(3 Pt 1):856-60. View

Gittelman M, Hertzman B, Bailen J, Williams T, Koziol I, Henderson R . PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013; 190(1):64-9. DOI: 10.1016/j.juro.2013.02.018. View

10.

Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F . Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging. J Clin Oncol. 2003; 21(15):2860-8. DOI: 10.1200/JCO.2003.11.130. View

11.

Radwan M, Yan Y, Luly J, Figenshau R, Brandes S, Bhayani S . Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology. 2007; 69(6):1121-7. DOI: 10.1016/j.urology.2007.01.087. View

12.

Vickers A, Cronin A, Aus G, Pihl C, Becker C, Pettersson K . Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer. 2010; 116(11):2612-20. PMC: 2882167. DOI: 10.1002/cncr.25010. View

13.

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J . Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015; 68(3):354-60. DOI: 10.1016/j.eururo.2014.12.006. View

14.

Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O . 15-year followup of a population based prostate cancer screening study. J Urol. 2009; 181(4):1615-21. DOI: 10.1016/j.juro.2008.11.115. View

15.

Eastham J, Riedel E, Scardino P, Shike M, Fleisher M, Schatzkin A . Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003; 289(20):2695-700. DOI: 10.1001/jama.289.20.2695. View

16.

Oliver S, Gunnell D, Donovan J . Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000; 355(9217):1788-9. DOI: 10.1016/s0140-6736(00)02269-8. View

17.

Loeb S, Sanda M, Broyles D, Shin S, Bangma C, Wei J . The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2014; 193(4):1163-9. PMC: 4404198. DOI: 10.1016/j.juro.2014.10.121. View

18.

Foley R, Maweni R, Gorman L, Murphy K, Lundon D, Durkan G . European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016; 118(5):706-713. DOI: 10.1111/bju.13437. View

19.

Latini D, Hart S, Knight S, Cowan J, Ross P, DuChane J . The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007; 178(3 Pt 1):826-31. DOI: 10.1016/j.juro.2007.05.039. View

20.

Gupta A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino P . A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer. 2010; 103(5):708-14. PMC: 2938258. DOI: 10.1038/sj.bjc.6605815. View